Anika Therapeutics, Inc. (NASDAQ:ANIK) Q2 2025 Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q2 2025 Earnings Call Transcript July 30, 2025Anika Therapeutics, Inc. reports earnings inline with expectations.
Anika Therapeutics Inc. (ANIK)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Trigran Investments Douglas T. Granat | 2,036,511 | $21,546,286 | -1% | 3.74% |
| 2. | Caligan Partners David Johnson | 1,435,130 | $15,183,675 | 2.92% | |
| 3. | Opaleye Management James A. Silverman | 588,797 | $6,229,472 | +50% | 1.26% |
| 4. | Renaissance Technologies Jim Simons | 527,217 | $5,577,956 | -1% | 0.01% |
| 5. | Alta Fundamental Advisers Jeremy Carton And Gilbert Li | 454,944 | $4,813,308 | -4% | 2.47% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $21.37 | 1,500 | $32,055.00 | 9,867 | 2022-05-11 | Filing | |
| $26.65 | 1,500 | $39,978.00 | 8,367 | 2022-03-14 | Filing | |
| $24.66 | 2,000 | $49,318.00 | 17,121 | 2022-03-11 | Filing | |
| $25.81 | 3,813 | $98,428.78 | 59,992 | 2022-03-11 | Filing | |
| $25.36 | 4,287 | $108,714.03 | 56,179 | 2022-03-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $42.60 | 2,000 | $85,200.00 | 7,953 | 2021-05-12 | Filing | |
| $36.77 | 3,446 | $126,709.42 | 9,953 | 2020-11-10 | Filing | |
| $35.15 | 1,244 | $43,726.60 | 1,756 | 2020-07-09 | Filing | |
| $42.68 | 2,700 | $115,236.00 | 13,399 | 2020-02-26 | Filing | |
| $59.71 | 20,000 | $1,194,200.00 | 47,741 | 2019-11-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,528,286 | $16,169,267 | 0% | |
| 2. | 779,473 | $8,246,824 | 0% | |
| 3. | 623,084 | $6,592,379 | 0% | |
| 4. | 529,503 | $5,602,142 | 0.11% | |
| 5. | 408,845 | $4,325,580 | 0.74% |
News See All
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen. Welcome to Anika's First Quarter Earnings Conference Call. At this time, all lines are in listen-only mode.
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to Anika's Fourth Quarter and Year End Earnings Conference Call. At this time, all lines are in listen-only mode.
12 Best Small Cap Pharma Stocks to Buy Now
Emily Field, Head of European Pharma Research at Barclays, spoke on CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical ...
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to Anika's Third Quarter Earnings Conference Call. [Operator Instructions].
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to Anika’s Second Quarter 2024 Earnings Conference Call.
Top 10 Holdings of Caligan Partners
Founded in 2017, Caligan Partners is one of the most significant specialty hedge funds.
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2024 Earnings Call Transcript
Anika Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.30712 EPS, expectations were $-0.19. Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2023 Earnings Call Transcript
Anika Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-4.3 EPS, expectations were $-0.26.
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2023 Earnings Call Transcript
Operator: Good evening, ladies and gentlemen, and welcome to Anika's Third Quarter 2023 Earnings Conference Call. All participants' will be in a listen-only mode.